CINC424D2301 (REACH3)

CINC424D2301 (REACH3)

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease (GVHD) After Allogeneic Stem Cell Transplantation (REACH3)


Treatment


Inclusion criteria


Exclusion criteria


Participating sites

Link